Opus Genetics Files 8-K

TL;DR

Opus Genetics filed an 8-K, standard procedure, check for details.

AI Summary

Opus Genetics, Inc. filed an 8-K on January 14, 2025, reporting "Other Events" and "Financial Statements and Exhibits" as of January 13, 2025. The company, formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceuticals, Inc., is incorporated in Delaware and based in Durham, NC.

Why It Matters

This filing indicates Opus Genetics is providing updates and financial information to the SEC, which is standard for publicly traded companies and can signal upcoming disclosures or events.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting standard corporate events and financial information, not indicating any immediate material changes or risks.

Key Players & Entities

• Opus Genetics, Inc. (company) — Registrant
• January 13, 2025 (date) — Earliest event date
• January 14, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Durham, NC (location) — Principal executive offices
• Ocuphire Pharma, Inc. (company) — Former company name
• Rexahn Pharmaceuticals, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IRD The Nasdaq
• $40,000,000 — th an aggregate offering price of up to $40,000,000 (the " Offering "), establishing an at
• $26.4 million — gate gross sales price of approximately $26.4 million of Shares have been sold under the Prio

Filing Documents

• ny20040461x2_8k.htm (8-K) — 31KB
• ny20040461x2_ex1-1.htm (EX-1.1) — 293KB
• ny20040461x2_ex5-1.htm (EX-5.1) — 11KB
• ny20040461x2_ex5-1image01.jpg (GRAPHIC) — 34KB
• 0001140361-25-001013.txt ( ) — 589KB
• ird-20250113.xsd (EX-101.SCH) — 4KB
• ird-20250113_lab.xml (EX-101.LAB) — 21KB
• ird-20250113_pre.xml (EX-101.PRE) — 16KB
• ny20040461x2_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. On January 13, 2025, Opus Genetics, Inc. , a Delaware corporation (the " Company "), filed a new prospectus supplement (the " Prospectus Supplement ") with the U.S. Securities and Exchange Commission (the " SEC ") with respect to the offer and sale of shares of its common stock, par value $0.0001 per share (the " Shares "), with an aggregate offering price of up to $40,000,000 (the " Offering "), establishing an at-the-market equity issuance program. On January 13, 2025, the Company also entered into a sales agreement (the " Sales Agreement ") by and between the Company and Leerink Partners LLC (" Leerink Partners ") through or to which the Company will sell the Shares. Any Shares offered and sold in the Offering will be issued pursuant to the Company's Registration Statement on Form S-3 (File No. 333-276462), which was declared effective on January 23, 2024, the Prospectus Supplement, which forms a part of the Registration Statement, and the Sales Agreement. The Company currently intends to use the net proceeds from the Offering, if any, for general corporate purposes, including for preclinical studies and clinical trials and the advancement of our product candidates. As of the date of the Prospectus Supplement, the Company cannot specify with certainty all of the particular uses for the net proceeds from this Offering, if any. As a result, the Company's management team will have broad discretion regarding the timing and application of the net proceeds from this Offering. Pending the application of the net proceeds, the Company intends to invest the net proceeds in interest-bearing, investment-grade securities, certificates of deposit or government securities. Leerink Partners may sell the Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Stock Market LLC (" Nasdaq ") or on any oth

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Sales Agreement, dated January 13, 2025, between the Company and Leerink Partners LLC 5.1 Opinion of Sidley Austin LLP 23.1 Consent of Sidley Austin LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 14, 2025 OPUS GENETICS, INC. By: /s/ Dr. George Magrath Name: Dr. George Magrath Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR